US FDA Approves Generic Medicine of Zydus Lifescience


The drug producing company ‘Zydus Lifescience’ has received the approval for the purpose of marketing the Famotidine tablets in the strengths of 20mg and 40mg respectively. The drug ‘Famotidine’ has been a histamine of H2 receptor blocker and it is also working by decreasing the amount of acid in the stomach.

The drug is also used for preventing and treating the heartburn and other symptoms has been caused by the excessive acid in the stomach. The drug is going to be manufactured at Zydus Lifesciences and its drug formulation facility at the company site. The Famotidine tablet is having a market size of 67 million dollars.

The company ‘Zydus Group’ is now having 315 approvals and so far the company has now filed more than 420 ANDAs since the establishment of the process of filing in the financial year 2003-2004.

Zydus Lifesciences has been a discovery-driven and the global lifesciences company that mainly develops, manufactures, discovers and is also marketing a broad range of the therapies of healthcare and the company has also reported a decrease of 41.5 percent decrease in the consolidated net profit in spite of an increase of 5.3 percent in the total income from the operations in the fourth quarter of 2021.

READ  US Government Commits $1-Billion Investment to Widen Covid-19 At-Home Tests